A long-term follow-up of botulinum toxin A in cervical dystonia.
OBJECTIVE
Cervical dystonia (CD) is the most common form of adult-onset focal dystonia, and botulinum toxin A (BoNT-A) has become the first-line treatment for this condition.


METHODS
In this work, we present data of 207 CD patients treated with BoNT-A for 6.7 +/- 3.5 years. One hundred and sixty-three patients were treated with Dysport (mean dose, 389 +/- 144 U) and 44 with Botox (mean dose, 145 +/- 44 U).


RESULTS
The mean clinical benefit, based on a 0-3 scale (0=no effect, 1=slight, 2=moderate and 3=marked improvement) was similar for Dysport (2.5 +/- 0.3) and Botox (2.2 +/- 0.4). Adverse events were mild and similar for both products. Fewer than 2% of the patients developed neutralizing antibodies.


CONCLUSIONS
These data confirm the efficacy and safety of BoNT-A treatment in CD over an extended period of up to 14 years.
Mohammadi
B
B
Department of Neurology and Clinical Neurophysiology, Hannover Medical School, Hannover, Germany. mohammadi.bahram@mh-hannover.de
Buhr
N
N
Bigalke
H
H
Krampfl
K
K
Dengler
R
R
Kollewe
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014103:Torticollis / Q000188:drug therapy*; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A